Condition (MeSH)
Ganglioneuroma
ClinicalTrials.gov lists 11 trials for Ganglioneuroma or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Ganglioneuroma itself; the rest are tagged with a narrower condition beneath it.
When did Ganglioneuroma trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2013 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ganglioneuroma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 5 |
How many Ganglioneuroma trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Completed | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ganglioneuroma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 2 |
| Children's Oncology Group | 1 |
Which drugs are being tested for Ganglioneuroma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| GSK1120212 | 2 |
| Dabrafenib | 2 |
| Irinotecan | 1 |
| Mirdametinib | 1 |
| 68Ga DOTATATE | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 1 |
| Positron Emission Tomography (PET) | 1 |
| 18F-FDG PET/CT | 1 |
| 68Ga-DOTATOC PET/CT | 1 |
| Vincristina | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ganglioneuroma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 23 | 1 |
| Headache | 6 | 1 |
| Hydrocephalus | 4 | 1 |
| Seizure | 4 | 1 |
| Vomiting | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Ganglioneuroma? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Trigeminal Ganglioneuroma: A Rare Case of Trigeminal Neuralgia Caused by Cerebellopontine Angle Tumor. | World neurosurgery | 2017 | Yes |
| Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. | BMC cancer | 2016 | Yes |
| The use of spinal angiography in the management of posterior mediastinal tumors: case series and review of the literature. | Journal of pediatric surgery | 2013 | Yes |
| Postoperative paraplegia after resection of a giant posterior mediastinal tumour. Importance of the blood supply in the upper spinal cord. | Interactive cardiovascular and thoracic surgery | 2011 | Yes |
| Retrospective study of childhood ganglioneuroma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2008 | Yes |
Showing 5 of 13 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Gangliocytoma | Annual incidence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ganglioneuroma | 251992 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Ganglioneuroma | 251992 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.